EU drug firms face new rules on variations from August
This article was originally published in SRA
Executive Summary
In yet another move prompted by the overhaul of EU pharmacovigilance legislation, the European Medicines Agency has issued revised guidance on the new rules on variations to existing marketing authorizations, including changes to risk management plans (RMPs)1,2.